Gap finder

Search review questions

Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.

Population

Intervention or exposure

Comparison

Outcome

Any field or review title

Field or topic

Source

Review versions

2,589 questions in 168 reviews · Schizophrenia

current versions

No studies 601 · 23.2%Ungraded 446 · 17.2%Very low 721 · 27.8%Low 505 · 19.5%Moderate 274 · 10.6%High 42 · 1.6%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Question	Effect	Evidence	Status / GRADE
HALOPERIDOL vs OTHER ANTIPSYCHOTIC: b. CHLORPROMAZINE Repeated need for rapid tranquillisation ‐ more that 1 injection · patients with psychosis‐induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	RR 1.07 [0.89, 1.28]	1 study · 30 participants	Very low
HALOPERIDOL vs COMBINATIONS: g. QUETIAPINE + MAGNESIUM VALPROATE Adverse effects ‐ any specific, serious ‐ not reported · patients with psychosis‐induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	no estimate extracted	NR	No studies
HALOPERIDOL vs COMBINATIONS: g. QUETIAPINE + MAGNESIUM VALPROATE Economic outcome ‐ not reported · patients with psychosis‐induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	no estimate extracted	0 studies · 0 participants	Ungraded
HALOPERIDOL vs COMBINATIONS: h. RISPERIDONE + CLONAZEPAM Tranquillisation or asleep · psychosis induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	RR 0.82 [0.66, 1.03]	1 study · 205 participants	Very low
HALOPERIDOL vs COMBINATIONS: h. RISPERIDONE + CLONAZEPAM Repeated need for tranquillisation ‐ not reported · psychosis induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	no estimate extracted	NR	No studies
HALOPERIDOL vs COMBINATIONS: h. RISPERIDONE + CLONAZEPAM Specific behaviour ‐ agitation · psychosis induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	no estimate extracted	1 study · 108 participants	Very low
HALOPERIDOL vs COMBINATIONS: h. RISPERIDONE + CLONAZEPAM Global outcome · psychosis induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	RR 0.6 [0.15, 2.38]	1 study · 100 participants	Low
HALOPERIDOL vs COMBINATIONS: h. RISPERIDONE + CLONAZEPAM Adverse effects · psychosis induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	RR 1.63 [1.12, 2.38]	1 study · 205 participants	Very low
HALOPERIDOL vs COMBINATIONS: h. RISPERIDONE + CLONAZEPAM Economic outcome ‐ not reported · psychosis induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	no estimate extracted	NR	No studies
HALOPERIDOL vs COMBINATIONS: i. ZIPRASIDONE + CLONAZEPAM Tranquillisation or asleep ‐ not reported · psychosis‐induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	no estimate extracted	NR	No studies
HALOPERIDOL vs COMBINATIONS: i. ZIPRASIDONE + CLONAZEPAM Repeated need for tranquillisation ‐ not reported · psychosis‐induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	no estimate extracted	NR	No studies
HALOPERIDOL vs OTHER ANTIPSYCHOTIC: b. CHLORPROMAZINE Specific behaviour ‐ threat or injury of harm to self or others ‐ not reported · patients with psychosis‐induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	no estimate extracted	NR	No studies
HALOPERIDOL vs COMBINATIONS: i. ZIPRASIDONE + CLONAZEPAM Specific behaviour ‐ agitation · psychosis‐induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	no estimate extracted	1 study · 71 participants	Very low
HALOPERIDOL vs COMBINATIONS: i. ZIPRASIDONE + CLONAZEPAM Global outcome ‐ no improvement ‐ not reported · psychosis‐induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	no estimate extracted	NR	No studies
HALOPERIDOL vs COMBINATIONS: i. ZIPRASIDONE + CLONAZEPAM Adverse effects ‐ not reported · psychosis‐induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	no estimate extracted	NR	No studies
HALOPERIDOL vs COMBINATIONS: i. ZIPRASIDONE + CLONAZEPAM Economic outcome ‐ not reported · psychosis‐induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	no estimate extracted	NR	No studies
HALOPERIDOL vs OTHER ANTIPSYCHOTIC: b. CHLORPROMAZINE Global outcome ‐ not any improvement · patients with psychosis‐induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	RR 0.15 [0.05, 0.49]	2 studies · 89 participants	Very low
HALOPERIDOL vs OTHER ANTIPSYCHOTIC: b. CHLORPROMAZINE Adverse effects: specific ‐ cardiovascular ‐ hypotension · patients with psychosis‐induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	RR 0.51 [0.01, 2.6]	1 study · 30 participants	Very low
HALOPERIDOL vs OTHER ANTIPSYCHOTIC: b. CHLORPROMAZINE Adverse effects: specific ‐ central nervous system ‐ seizures · patients with psychosis‐induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	RR 0.33 [0.01, 7.58]	1 study · 30 participants	Very low
HALOPERIDOL vs OTHER ANTIPSYCHOTIC: b. CHLORPROMAZINE Economic outcome ‐ not reported · patients with psychosis‐induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	no estimate extracted	NR	No studies
HALOPERIDOL vs PLACEBO/NIL Repeated need for tranquillisation needing additional injection within 24 hours · patients with psychosis‐induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	RR 0.51 [0.42, 0.62]	4 studies · 660 participants	Low
HALOPERIDOL vs OTHER ANTIPSYCHOTIC: c. DROPERIDOL Tranquillisation or asleep ‐ not asleep up to 2 hours · psychosis‐induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	RR 1.07 [0.44, 2.6]	1 study · 228 participants	Moderate
HALOPERIDOL vs OTHER ANTIPSYCHOTIC: c. DROPERIDOL Repeated need for rapid tranquillisation ‐ more than 1 injection · psychosis‐induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	RR 2.38 [1.27, 4.47]	2 studies · 255 participants	Moderate
HALOPERIDOL vs OTHER ANTIPSYCHOTIC: c. DROPERIDOL Specific behaviour ‐ threat or injury to self or others ‐ not reported · psychosis‐induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	no estimate extracted	NR	No studies
HALOPERIDOL vs OTHER ANTIPSYCHOTIC: c. DROPERIDOL Global outcome ‐ need for benzodiazepine · psychosis‐induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	RR 0.31 [0.07, 1.44]	1 study · 228 participants	Moderate
HALOPERIDOL vs OTHER ANTIPSYCHOTIC: c. DROPERIDOL Adverse effects: specific ‐ dystonia · psychosis‐induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	RR 0.86 [0.11, 6.56]	2 studies · 255 participants	Moderate
HALOPERIDOL vs OTHER ANTIPSYCHOTIC: c. DROPERIDOL Economic outcome ‐ not reported · psychosis‐induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	no estimate extracted	NR	No studies
HALOPERIDOL vs OTHER ANTIPSYCHOTIC: d. LOXAPINE Tranquillisation or asleep ‐ not asleep by 12 hours · patients to psychosis‐induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	RR 4.31 [0.54, 34.48]	1 study · 54 participants	Very low
HALOPERIDOL vs OTHER ANTIPSYCHOTIC: d. LOXAPINE Global outcome: specific Not sedated at 60 minutes * · patients to psychosis‐induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	RR 3.5 [0.86, 14.18]	1 study · 30 participants	Very low
HALOPERIDOL vs OTHER ANTIPSYCHOTIC: d. LOXAPINE Specific behaviour ‐ aggression ‐ no overall improvement · patients to psychosis‐induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	RR 1.1 [0.69, 1.76]	1 study · 30 participants	Very low
HALOPERIDOL vs OTHER ANTIPSYCHOTIC: d. LOXAPINE Global outcome: no change at 48 hours CGI · patients to psychosis‐induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	RR 0.93 [0.14, 6.15]	1 study · 56 participants	Low
HALOPERIDOL vs PLACEBO/NIL Specific behaviour ‐ threat or injury to self or others average change score (ABS, high = worse) at 2 hours · patients with psychosis‐induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	no estimate extracted	3 studies · 474 participants	Very low
HALOPERIDOL vs OTHER ANTIPSYCHOTIC: d. LOXAPINE Adverse effects: Specific ‐ dystonia between 0‐3 days (IM phase) · patients to psychosis‐induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	RR 0.94 [0.06, 13.93]	1 study · 35 participants	Very low
HALOPERIDOL vs OTHER ANTIPSYCHOTIC: d. LOXAPINE Adverse effects: Specific ‐ rigidity between 0‐3 days (IM phase) · patients to psychosis‐induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	RR 0.88 [0.65, 1.19]	1 study · 35 participants	Very low
HALOPERIDOL vs OTHER ANTIPSYCHOTIC: d. LOXAPINE Economic outcome ‐ not reported · patients to psychosis‐induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	no estimate extracted	NR	No studies
HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE Tranquilisation or asleep · psychosis induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	RR 1.16 [1.02, 1.32]	1 study · 257 participants	Very low
HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE Repeated need for tranquillisation · psychosis induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	RR 1.06 [0.75, 1.51]	3 studies · 392 participants	Very low
HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE Specific behaviour ‐ threat or injury to self or others · psychosis induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	RR 0.96 [0.58, 1.58]	1 study · 45 participants	Very low
HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE Global outcome ‐ need for benzodiazepine during 24 hours · psychosis induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	RR 1.05 [0.63, 1.74]	2 studies · 343 participants	Very low
HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE Adverse effects: Specific ‐ dystonia during 24 hours · psychosis induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	RR 12.92 [1.67, 99.78]	2 studies · 343 participants	Very low
HALOPERIDOL vs OTHER ANTIPSYCHOTIC: e. OLANZAPINE Economic outcome ‐ not reported · psychosis induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	no estimate extracted	NR	No studies
HALOPERIDOL vs OTHER ANTIPSYCHOTIC: f. PERPHENAZINE Tranquillisation or asleep ‐ not reported · patients with psychosis‐induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	no estimate extracted	NR	No studies
HALOPERIDOL vs PLACEBO/NIL Global outcome ‐ overall improvement (not any improvement) · patients with psychosis‐induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	RR 0.28 [0.08, 1.07]	1 study · 40 participants	Low
HALOPERIDOL vs OTHER ANTIPSYCHOTIC: f. PERPHENAZINE Repeated need for rapid tranquillisation ‐ not reported · patients with psychosis‐induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	no estimate extracted	NR	No studies
HALOPERIDOL vs OTHER ANTIPSYCHOTIC: f. PERPHENAZINE Specific behaviour ‐ injury or threat of self to others ‐ not reported · patients with psychosis‐induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	no estimate extracted	NR	No studies
HALOPERIDOL vs OTHER ANTIPSYCHOTIC: f. PERPHENAZINE Global outcome: general ‐ no improvement · patients with psychosis‐induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	RR 0.46 [0.04, 4.68]	1 study · 44 participants	Very low
HALOPERIDOL vs OTHER ANTIPSYCHOTIC: f. PERPHENAZINE Adverse effect: Specific ‐ hypotensive episode · patients with psychosis‐induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	RR 0.31 [0.01, 7.12]	1 study · 44 participants	Very low
HALOPERIDOL vs OTHER ANTIPSYCHOTIC: f. PERPHENAZINE Adverse effect ‐ discontinued due to EPS · patients with psychosis‐induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	RR 1.83 [0.18, 18.7]	1 study · 44 participants	Very low
HALOPERIDOL vs OTHER ANTIPSYCHOTIC: f. PERPHENAZINE Economic outcome ‐ not reported · patients with psychosis‐induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	no estimate extracted	NR	No studies
HALOPERIDOL vs OTHER ANTIPSYCHOTICS: g. QUETIAPINE Tranquillisation or asleep ‐ not reported · psychosis‐induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane	no estimate extracted	NR	No studies